ABSTRACT
A ß-galactosidase activatable fluorescent turn-on theranostic Gal-CGem exhibits gemcitabine release specifically in ß-galactosidase overexpressing hepatic carcinoma cells. The cytotoxicity of Gal-CGem in cancer cells is achieved through the apoptotic cell death pathway. Overall, Gal-CGem is a new frontline prodrug in cancer therapy that has provided antineoplastic information through fluorescence imaging.
Subject(s)
Carcinoma, Hepatocellular , Liver Neoplasms , Carcinoma, Hepatocellular/diagnostic imaging , Carcinoma, Hepatocellular/drug therapy , Fluorescent Dyes/metabolism , Fluorescent Dyes/pharmacology , Humans , Liver Neoplasms/diagnostic imaging , Liver Neoplasms/drug therapy , Optical Imaging/methods , Precision Medicine , Theranostic Nanomedicine/methods , beta-Galactosidase/metabolismABSTRACT
The endogenous H2S-driven theranostic H2S-Gem has been invented. The theranostic prodrug H2S-Gem is selectively activated in cancer cells, releasing active gemcitabine with a simultaneous fluorescence turn-on. H2S-Gem selectively inhibited cancer cell growth compared to the mother chemotherapeutic gemcitabine. Overall, it is a unique protocol for tracking and transporting chemotherapeutic agents to tumor areas without the guidance of tumor-directive ligands.
